Solid Tumor Cancer

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

InxMed
InxMedChina - Beijing
1 program
1
IN10018 in combination with RNK08954Phase 1/21 trial
Active Trials
NCT07441174Recruiting92Est. Feb 2031
Abdera Therapeutics
Abdera TherapeuticsBC - Vancouver
1 program
1
111In-ABD147Phase 11 trial
Active Trials
NCT07052760Not Yet RecruitingEst. Dec 2027

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
2030
2031
InxMedIN10018 in combination with RNK08954
Abdera Therapeutics111In-ABD147

Clinical Trials (2)

Total enrollment: 92 patients across 2 trials

NCT07441174InxMedIN10018 in combination with RNK08954

IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

Start: Feb 2026Est. completion: Feb 203192 patients
Phase 1/2Recruiting

Imaging of Solid Tumors Using DLL3 SPECT

Start: Nov 2025Est. completion: Dec 2027
Phase 1Not Yet Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 92 patients
2 companies competing in this space